These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15667590)

  • 1. Herbal or natural medicines as modulators of peroxisome proliferator-activated receptors and related nuclear receptors for therapy of metabolic syndrome.
    Huang TH; Kota BP; Razmovski V; Roufogalis BD
    Basic Clin Pharmacol Toxicol; 2005 Jan; 96(1):3-14. PubMed ID: 15667590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome.
    Guan Y
    J Am Soc Nephrol; 2004 Nov; 15(11):2801-15. PubMed ID: 15504933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome.
    Huang TH; Teoh AW; Lin BL; Lin DS; Roufogalis B
    Pharmacol Res; 2009 Sep; 60(3):195-206. PubMed ID: 19646659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD
    Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPAR agonists and the metabolic syndrome.
    Staels B
    Therapie; 2007; 62(4):319-26. PubMed ID: 17983557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPARs as targets for the modulation of cardiovascular risk factors associated with the metabolic syndrome.
    Fernandez AZ
    Curr Opin Investig Drugs; 2004 Sep; 5(9):936-40. PubMed ID: 15503647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The metabolic syndrome: relationship between insulin sensitivity and the role of peroxisome proliferator-activated receptors (PPARs) in saccharide and lipid metabolism.
    Yahia RB; Lichnovská R; Brychta T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):237-41. PubMed ID: 16601762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skeletal muscle and nuclear hormone receptors: implications for cardiovascular and metabolic disease.
    Smith AG; Muscat GE
    Int J Biochem Cell Biol; 2005 Oct; 37(10):2047-63. PubMed ID: 15922648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy.
    Chinetti-Gbaguidi G; Fruchart JC; Staels B
    Curr Opin Pharmacol; 2005 Apr; 5(2):177-83. PubMed ID: 15780828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FXR: a promising target for the metabolic syndrome?
    Cariou B; Staels B
    Trends Pharmacol Sci; 2007 May; 28(5):236-43. PubMed ID: 17412431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioactive lipids in metabolic syndrome.
    Nagao K; Yanagita T
    Prog Lipid Res; 2008 Mar; 47(2):127-46. PubMed ID: 18177744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
    Libby P; Plutzky J
    Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms of action of the soy isoflavones includes activation of promiscuous nuclear receptors. A review.
    Ricketts ML; Moore DD; Banz WJ; Mezei O; Shay NF
    J Nutr Biochem; 2005 Jun; 16(6):321-30. PubMed ID: 15936643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
    Steiner G
    Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
    Blaschke F; Takata Y; Caglayan E; Law RE; Hsueh WA
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):28-40. PubMed ID: 16239592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptors and the metabolic syndrome.
    Bragt MC; Popeijus HE
    Physiol Behav; 2008 May; 94(2):187-97. PubMed ID: 18191967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease.
    Rana JS; Nieuwdorp M; Jukema JW; Kastelein JJ
    Diabetes Obes Metab; 2007 May; 9(3):218-32. PubMed ID: 17391148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease.
    Bouhlel MA; Staels B; Chinetti-Gbaguidi G
    J Intern Med; 2008 Jan; 263(1):28-42. PubMed ID: 18042221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dietary modulators of peroxisome proliferator-activated receptors: implications for the prevention and treatment of metabolic syndrome.
    Guri AJ; Hontecillas R; Bassaganya-Riera J
    J Nutrigenet Nutrigenomics; 2008; 1(3):126-35. PubMed ID: 19776622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy.
    Wyne KL
    Diabetes Obes Metab; 2006 Jul; 8(4):365-80. PubMed ID: 16776743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.